Peptides as Targeting Elements and Tissue Penetration Devices for Nanoparticles

The use of nanoparticles in medicine (nanomedicine) has recently become an intensely studied field. Nanoparticles carrying drugs and imaging agents have already reached the clinic, but they are essentially passive delivery vehicles, not what are referred to as "smart" nanoparticles. An important function to add to make nanoparticles smarter is active homing to the target tissue. It makes nanoparticles accumulate in the target tissue at higher concentrations than would be the case without this feature, increasing therapeutic efficacy and reducing side effects. This review discusses the recent developments in the nanoparticle targeting field with emphasis on peptides that home to vascular "zip codes" in target tissues and provide a tissue- and cell-penetrating function.

[1]  Michael J Sailor,et al.  SERS‐Coded Gold Nanorods as a Multifunctional Platform for Densely Multiplexed Near‐Infrared Imaging and Photothermal Heating , 2009, Advanced materials.

[2]  Sangeeta N. Bhatia,et al.  Intracellular Delivery of Quantum Dots for Live Cell Labeling and Organelle Tracking , 2004 .

[3]  D. Cheresh,et al.  Tumor angiogenesis: molecular pathways and therapeutic targets , 2011, Nature Medicine.

[4]  K. Kinzler,et al.  Cell surface tumor endothelial markers are conserved in mice and humans. , 2001, Cancer research.

[5]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[6]  Ji-Ho Park,et al.  Cooperative nanomaterial system to sensitize, target, and treat tumors , 2009, Proceedings of the National Academy of Sciences.

[7]  Erkki Ruoslahti,et al.  Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. , 2008, Cancer research.

[8]  Miriam Scadeng,et al.  Development of a novel mouse glioma model using lentiviral vectors , 2009, Nature Medicine.

[9]  Erkki Ruoslahti,et al.  Tissue-penetrating delivery of compounds and nanoparticles into tumors. , 2009, Cancer cell.

[10]  S. Seaman,et al.  Genes that distinguish physiological and pathological angiogenesis. , 2007, Cancer cell.

[11]  Wadih Arap,et al.  Reversal of obesity by targeted ablation of adipose tissue , 2004, Nature Medicine.

[12]  E. Pardon,et al.  Specificity of adhesion between murine tumor cells and capillary endothelium: an in vitro correlate of preferential metastasis in vivo. , 1987, Cancer research.

[13]  B. Davidson,et al.  Transvascular delivery of small interfering RNA to the central nervous system , 2007, Nature.

[14]  E. Ruoslahti,et al.  Mapping of vascular ZIP codes by phage display. , 2012, Methods in enzymology.

[15]  Yan Li,et al.  Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy , 2004, Nature.

[16]  Raoul Kopelman,et al.  Vascular Targeted Nanoparticles for Imaging and Treatment of Brain Tumors , 2006, Clinical Cancer Research.

[17]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[18]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[19]  Ülo Langel,et al.  Design of a Tumor-Homing Cell-Penetrating Peptide , 2008 .

[20]  R K Jain,et al.  Transport of molecules, particles, and cells in solid tumors. , 1999, Annual review of biomedical engineering.

[21]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[22]  Erkki Ruoslahti,et al.  Targeting atherosclerosis by using modular, multifunctional micelles , 2009, Proceedings of the National Academy of Sciences.

[23]  Jun Yao,et al.  Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. , 2006, Cancer research.

[24]  E. Ruoslahti,et al.  Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice , 2011, Proceedings of the National Academy of Sciences.

[25]  R Pasqualini,et al.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.

[26]  Ruth Nussinov,et al.  Nanoparticle-induced vascular blockade in human prostate cancer. , 2010, Blood.

[27]  J. Lahann.  Recent progress in nano-biotechnology: compartmentalized micro- and nanoparticles via electrohydrodynamic co-jetting. , 2011, Small.

[28]  Jianghong Rao,et al.  A biocompatible condensation reaction for controlled assembly of nanostructures in live cells , 2010, Nature chemistry.

[29]  M. McConnell,et al.  Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions. , 2011, ACS nano.

[30]  E. Ruoslahti,et al.  Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[31]  E. Ruoslahti.  Specialization of tumour vasculature , 2002, Nature Reviews Cancer.

[32]  Erkki Ruoslahti,et al.  Membrane Dipeptidase Is the Receptor for a Lung-targeting Peptide Identified by in Vivo Phage Display* , 1999, The Journal of Biological Chemistry.

[33]  A. M. Rush,et al.  X-ray computed tomography imaging of breast cancer by using targeted peptide-labeled bismuth sulfide nanoparticles. , 2011, Angewandte Chemie.

[34]  S. Dowdy,et al.  TAT transduction: the molecular mechanism and therapeutic prospects. , 2007, Trends in molecular medicine.

[35]  E. Ruoslahti,et al.  Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. , 2004, Cancer cell.

[36]  O. G. Ramprasad,et al.  Lipopeptide with a RGDK tetrapeptide sequence can selectively target genes to proangiogenic alpha5beta1 integrin receptor and mouse tumor vasculature. , 2008, Journal of medicinal chemistry.

[37]  Neetu Singh,et al.  Nanoparticles that communicate in vivo to amplify tumour targeting. , 2011, Nature materials.

[38]  E. Ruoslahti,et al.  Molecular changes in the vasculature of injured tissues. , 2007, The American journal of pathology.

[39]  E. Ruoslahti,et al.  Peptide-directed highly selective targeting of pulmonary arterial hypertension. , 2011, The American journal of pathology.

[40]  Peter Carmeliet,et al.  Molecular mechanisms of lymphangiogenesis in health and disease. , 2002, Cancer cell.

[41]  Angelo Corti,et al.  Tumor vasculature targeting through NGR peptide-based drug delivery systems. , 2011, Current pharmaceutical biotechnology.

[42]  D. Hanahan,et al.  Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. , 2003, Cancer cell.

[43]  Erkki Ruoslahti,et al.  Peptides targeting inflamed synovial vasculature attenuate autoimmune arthritis , 2011, Proceedings of the National Academy of Sciences.

[44]  H. Dvorak,et al.  Regulation of extravascular coagulation by microvascular permeability. , 1985, Science.

[45]  Yong-Eun Koo Lee,et al.  F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. , 2010, Cancer research.

[46]  Walter Heindel,et al.  Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. , 2009, Blood.

[47]  M. Tessier-Lavigne,et al.  Neuropilins in Tumor Biology , 2009, Clinical Cancer Research.

[48]  R. DePinho,et al.  Targeted Nanoparticles for Imaging Incipient Pancreatic Ductal Adenocarcinoma , 2007, PLoS medicine.

[49]  E. Ruoslahti.  The RGD story: a personal account. , 2003, Matrix biology : journal of the International Society for Matrix Biology.

[50]  Erkki Ruoslahti,et al.  Nanocrystal targeting in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Michele Bernasconi,et al.  Furin Targeted Drug Delivery for Treatment of Rhabdomyosarcoma in a Mouse Model , 2010, PloS one.

[52]  Erkki Ruoslahti,et al.  Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels , 2003, The Journal of cell biology.

[53]  Erkki Ruoslahti,et al.  A tumor-homing peptide with a targeting specificity related to lymphatic vessels , 2002, Nature Medicine.

[54]  Michael J Sailor,et al.  Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. , 2009, Small.

[55]  S. Nisole,et al.  The Anti-HIV Cytokine Midkine Binds the Cell Surface-expressed Nucleolin as a Low Affinity Receptor* , 2002, The Journal of Biological Chemistry.

[56]  P. Nawroth,et al.  Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Erkki Ruoslahti,et al.  Organ targeting In vivo using phage display peptide libraries , 1996, Nature.

[58]  M. El-Sayed,et al.  Nuclear targeting of gold nanoparticles in cancer cells induces DNA damage, causing cytokinesis arrest and apoptosis. , 2010, Journal of the American Chemical Society.

[59]  Samir Mitragotri,et al.  Macrophages Recognize Size and Shape of Their Targets , 2010, PloS one.

[60]  A. Bobkov,et al.  Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide , 2011, Proceedings of the National Academy of Sciences.

[61]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[62]  R. Longhi,et al.  Coupling Tumor Necrosis Factor-α with αV Integrin Ligands Improves Its Antineoplastic Activity , 2004, Cancer Research.

[63]  Roger Y Tsien,et al.  Tumor imaging by means of proteolytic activation of cell-penetrating peptides. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Erkki Ruoslahti,et al.  Targeting of drugs and nanoparticles to tumors , 2010, The Journal of cell biology.

[65]  Erkki Ruoslahti,et al.  Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.

[66]  E. Ruoslahti,et al.  C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration , 2009, Proceedings of the National Academy of Sciences.

[67]  Jianghong Rao,et al.  Controlling intracellular macrocyclization for the imaging of protease activity. , 2011, Angewandte Chemie.

[68]  Erkki Ruoslahti,et al.  Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs , 2010, Science.

[69]  P. Scifo,et al.  Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. , 2010, European journal of cancer.

[70]  R. Béliveau,et al.  New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. , 2010, Journal of medicinal chemistry.

[71]  S. Stupp,et al.  Induction of cancer cell death by self-assembling nanostructures incorporating a cytotoxic peptide. , 2010, Cancer research.

[72]  Erkki Ruoslahti,et al.  Targeting the prostate for destruction through a vascular address , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[73]  Erkki Ruoslahti,et al.  Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. , 2003, Cancer cell.

[74]  H. Maeda,et al.  Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.

[75]  R. Langer,et al.  In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid–polymeric nanoparticles , 2011, Proceedings of the National Academy of Sciences.

[76]  Erkki Ruoslahti,et al.  Targeting of albumin-embedded paclitaxel nanoparticles to tumors. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[77]  Erkki Ruoslahti,et al.  A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[78]  J. Arbeit,et al.  Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. , 2009, The Journal of clinical investigation.

[79]  E. Ruoslahti,et al.  Molecular Profiling of Heart Endothelial Cells , 2005, Circulation.

[80]  E. Ruoslahti,et al.  Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma , 2011, Proceedings of the National Academy of Sciences.

[81]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[82]  Michael J Sailor,et al.  Biomimetic amplification of nanoparticle homing to tumors , 2007, Proceedings of the National Academy of Sciences.

[83]  C. Rousselle,et al.  Improved Brain Delivery of Benzylpenicillin with a Peptide-vector-mediated Strategy , 2002, Journal of drug targeting.

[84]  E. Ruoslahti,et al.  Vascular zip codes in angiogenesis and metastasis. , 2004, Biochemical Society transactions.

[85]  Michael J Sailor,et al.  Biodegradable luminescent porous silicon nanoparticles for in vivo applications. , 2009, Nature materials.

[86]  A flexible and stereoselective synthesis of azetidin-3-ones through gold-catalyzed intermolecular oxidation of alkynes. , 2011, Angewandte Chemie.

[87]  D. Stolz,et al.  Identification of endothelial cell–surface proteins as targets for diagnosis and treatment of disease , 1996, Nature Medicine.

[88]  R. Giavazzi,et al.  A proteomic approach for the identification of vascular markers of liver metastasis. , 2010, Cancer research.

[89]  S. Pastorino,et al.  Transdifferentiation of glioblastoma cells into vascular endothelial cells , 2011, Proceedings of the National Academy of Sciences.